Lung cancer – one of the most commonly diagnosed cancers in the United States – is an area of intense research and clinical development. While there has been extraordinary progress …Read More
Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch several new funding initiatives to support innovative research focused on Tumor Treating Fields (TTFields). TTFields is a novel noninvasive cancer therapy approved by the U.S. Food and Drug Administration for the treatment of adults with glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Patients wear a portable electric field generator that delivers TTFields to tumors via electrodes attached to the skin over the tumor site.Read More
The Centers for Medicare & Medicaid Services offers value-based programs that “reward health care providers with incentive payments for the quality of care they give to people.” Many private insurers offer similar payment approaches or are considering how to do so. The hope is that financial rewards will go to physicians, hospitals and health systems that deliver the best patient outcomes, not simply generate the largest number of procedures, laboratory tests, radiographic images, and drugs.Read More
There has been an explosion in the number of cancer therapeutics and clinical trials in the recent past, owing to our ability to better define the molecular targets of different cancers using cutting-edge technologies. Unlike in the past, data from early-stage clinical trials are getting more attention lately because the efficacy of a therapeutic, traditionally evaluated in later-phase trials, is often becoming evident earlier in the course of clinical testing.Read More
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes altered in about a third of cancers, encouraging data emerging from clinical trials and preclinical studies suggest KRAS could finally be dethroned from the “undruggable” category.Read More
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in Boston Oct. 26-30, has once again brought together members of academia, pharmaceutical industry, federal regulatory agencies, and all other stakeholders in the cancer drug development space from across the globe to discuss the most up-to-date advances.
A couple of studies presented at the conference set out to address an important question in cancer research – why is ovarian cancer so hard to treat?Read More
As October comes to a close, it’s time for our latest edition of Editors’ Picks. This monthly staple is a collection of 10 “must read” articles that have been hand-selected by the editors from the portfolio of journals published by the AACR. This month, featured articles include results from three clinical trials and a look at cancer disparities among American Indians and Alaska Natives, among others. As always, articles highlighted here are freely available for a limited time.Read More
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula) to include an additional group of patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: those whose cancer has progressed despite treatment with at least three different cytotoxic chemotherapy regimens and tests positive for a new biomarker called homologous recombination deficiency (HRD).Read More
Sports are often referred to as a metaphor for life. But, for ESPN reporter Holly Rowe, sports are quite literally a way of life. When Rowe was undergoing treatment for desmoplastic melanoma, her passion for sports—and telling athletes’ stories from the sidelines—helped her muscle through her own personal struggles.Read More
As Greek mythology tells us, the titan Prometheus was punished by the gods for giving fire to man. His sentence? Eternal torture. Each day, an eagle would eat his liver, which would grow back overnight, ready to be devoured by the eagle again the next day.
The liver’s ability to regenerate presumably evolved to protect it from damage from food toxins. However, chronic cycles of liver damage and regeneration can lead to aberrant replication and eventually the development of liver cancer.Read More
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United States, it is estimated that over 40,000 women and roughly 500 men will die from breast cancer in 2019. Despite progress in developing new treatment modalities for patients with this disease, there is still substantial work to be done in the field.Read More